COVID-19 vaccine developer Moderna will build a state-of-the-art manufacturing facility in Quebec, Canada. The project is expected to create hundreds of jobs.
The new facility will be able to produce up to 100 million mRNA vaccine doses annually. Construction is set to start this year and the facility is expected to be operational in 2024 at the earliest, subject to planning and regulatory approvals.
“We are delighted to reach this landmark with the Government of Canada and bring a state-of-the-art mRNA facility to the people of Canada. The government has shown true leadership in the fight against COVID-19. We share a common vision for the fundamental need for pandemic preparedness in the face of future pandemics and health emergencies,” Stéphane Bancel, CEO, Moderna said.
In addition to COVID-19 vaccines, the facility is expected to be able to produce vaccines for other respiratory diseases, such as influenza, pending their ongoing development by Moderna and approval by Health Canada.
“Today’s announcement is yet another example of our promise to Canadians to have their back throughout this pandemic and beyond. From the outset, we took short-term strategic actions with a long-term vision to ensure that Canada is well prepared for future pandemics while also strengthening our economy and creating good jobs for Canadians. Moderna establishing their operations here in Canada is a testimony to that vision and to Canada’s attractiveness as a place to invest and to innovate,” The Hon. François-Philippe Champagne, Minister of Innovation, Science and Industry noted.
“One of our government’s top priorities is to protect the health and safety of people in Canada. Moderna’s new facility will strengthen domestic health security and pandemic preparedness through timely access to innovative, cutting-edge vaccines that help us save lives. Moderna’s presence will also further establish Canada as a global leader in mRNA technology, leading a new era of domestic health innovation,” The Hon. Jean-Yves Duclos, Minister of Health said.